Resistance-resistant antibiotics

Trends in Pharmacological Sciences

Volumn 35, Issue 12, 2014, Pages 664-674

  Oldfield, Eric ^a   Feng, Xinxin ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

antibiotics; innate immunity; isoprenoids; molecular dynamics; multitargeting; resistance

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ARSPHENAMINE; ARTEMISIN; CHLOROQUINE; COLISTIN; DIHYDROPTEROATE SYNTHASE; EFLORNITHINE; IVERMECTIN; MILTEFOSINE; PENICILLIN DERIVATIVE; POSACONAZOLE; QUININE; RISEDRONIC ACID; SULFAMIDOCHRYSOIDINE; SULFONAMIDE; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; CLOSTRIDIUM DIFFICILE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; GRAM NEGATIVE BACTERIUM; HELICOBACTER PYLORI; HIGH THROUGHPUT SCREENING; HUMAN; INNATE IMMUNITY; LEISHMANIA MEXICANA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR DYNAMICS; MYCOBACTERIUM TUBERCULOSIS; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; TRYPANOSOMA CRUZI; ANIMAL; CHEMISTRY; DRUG DESIGN;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, MICROBIAL; HUMANS; MOLECULAR DYNAMICS SIMULATION;

EID: 84913604131     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2014.10.007     Document Type: Review

References (82)

1. Centers for Disease Control and Prevention Threat Report 2013: Antibiotic/Antimicrobial Resistance 2013 Centers for Disease Control and Prevention
2. World Health Organization Antimicrobial Resistance: Global Report on Surveillance 2014 2014 World Health Organization
3. Y. Tu The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine Nat. Med. 17 2011 1217 1220
4. W. Cui, and Y. Zhou Ancient Chinese anti-fever cure becomes panacea for malaria Bull. World Health Organ. 87 2009 743 744
5. J. Zhang A Detailed Chronological Record of Project 523 and the Discovery and Development if Qinghaosu (Artemisinin) 2013 Strategic Book Publishing
6. M. Honigsbaum The Fever Trail: In Search of the Cure for Malaria 2002 Farrar, Straus and Giroux
7. P.J. Pelletier, and J.B. Caventou Suite des researches chimiques sur les quinquinas Ann. Chim. Phys. 15 1820 337 365
8. A.C. Hüntelmann Making Salvarsan: experimental therapy and the development and marketing of Salvarsan at the interface between science, clinic, industry and public health J-P. Gaudillière, V. Hess, Ways of Regulating Drugs in the 19th and 20th Centuries 2012 Palgrave Macmillan 43 65
9. N.C. Lloyd The composition of Ehrlich's salvarsan: resolution of a century-old debate Angew. Chem. Int. Ed. Engl. 44 2005 941 944
10. G. Domagk Nobel Lecture: Further Progress in Chemotherapy of Bacterial Infections 2013 Nobel Media
11. K. Hede Antibiotic resistance: an infectious arms race Nature 509 2014 S2 S3
12. R. Laxminarayan Antibiotic effectiveness: balancing conservation against innovation Science 345 2014 1299 1301
13. M. Leeb Antibiotics: a shot in the arm Nature 431 2004 892 893
14. C. Nathan Antibiotics at the crossroads Nature 431 2004 899 902
15. J. Reed, and A. Mullard An audience with John Reed Nat. Rev. Drug Discov. 13 2014 170 171
16. S. Davies The Drugs Don't Work: A Global Threat 2013 Penguin Books
17. A. Fleming Nobel Lecture: Penicillin Nobel Lectures, Physiology or Medicine 1942-1962 1945 Elsevier 83 93
18. F. Rossi Transferable vancomycin resistance in a community-associated MRSA lineage N. Engl. J. Med. 370 2014 1524 1531
19. C.J.L. Murray Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2197 2223
20. V. Lutje Chemotherapy for second-stage human African trypanosomiasis Cochrane Database Syst. Rev. 6 2013 CD006201
21. L.L. Silver Multi-targeting by monotherapeutic antibacterials Nat. Rev. Drug Discov. 6 2007 41 55
22. L.L. Silver Viable screening targets related to the bacterial cell wall Ann. N. Y. Acad. Sci. 1277 2013 29 53
23. U.S. Food, and Drug Administration Guidance for Industry - Codevelopment of Two or More New Investigational Drugs for Use in Combination 2013 US FDA
24. J.R. Morphy, and C.J. Harris Designing Multi-Target Drugs 2012 RSC Publishing
25. J.L. Medina-Franco Shifting from the single to the multitarget paradigm in drug discovery Drug Discov. Today 18 2013 495 501
26. F. Prati Two diseases, one approach: multitarget drug discovery in Alzheimer's and neglected tropical diseases MedChemComm 5 2014 853 861
27. S.P. East, and L.L. Silver Multitarget ligands in antibacterial research: progress and opportunities Expert Opin. Drug Discov. 8 2013 143 156
28. L.L. Silver Challenges of antibacterial discovery Clin. Microbiol. Rev. 24 2011 71 109
29. M.J. Pucci, and J.A. Wiles Bacterial topoisomerase inhibitors: quinolones and beyond Antimicrobials: New and Old molecules in the Fight Against Multi-Resistant Bacteria 2014 Springer Verlag 307 326
30. S. Khanna Additivity of molecular fields: CoMFA study on dual activators of PPAR alpha and PPAR gamma J. Med. Chem. 48 2005 3015 3025
31. W. Zhu Antibacterial drug leads targeting isoprenoid biosynthesis Proc. Natl. Acad. Sci. U.S.A. 110 2013 123 128
32. K. Li Multitarget drug discovery for tuberculosis and other infectious diseases J. Med. Chem. 57 2014 3126 3139
33. M. Rohmer From molecular fossils of bacterial hopanoids to the formation of isoprene units: discovery and elucidation of the methylerythritol phosphate pathway Lipids 43 2008 1095 1107
34. Y. Zhang HIV-1 integrase inhibitor-inspired antibacterials targeting isoprenoid biosynthesis ACS Med. Chem. Lett. 3 2012 402 406
35. D.J. Payne Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discov. 6 2007 29 40
36. S. Lindert Farnesyl diphosphate synthase inhibitors from in silico screening Chem. Biol. Drug Des. 81 2013 742 748
37. W. Sinko Applying molecular dynamics simulations to identify rarely sampled ligand-bound conformational states of undecaprenyl pyrophosphate synthase, an antibacterial target Chem. Biol. Drug Des. 77 2011 412 420
38. R.T. Guo Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases Proc. Natl. Acad. Sci. U.S.A. 104 2007 10022 10027
39. E. Oldfield Targeting isoprenoid biosynthesis for drug discovery: bench to bedside Acc. Chem. Res. 43 2010 1216 1226
40. M.B. Martin Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy J. Med. Chem. 44 2001 909 916
41. J.A. Urbina Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs J. Biol. Chem. 274 1999 33609 33615
42. I. Bruchhaus Pyrophosphate-dependent phosphofructokinase of Entamoeba histolytica: molecular cloning, recombinant expression and inhibition by pyrophosphate analogues Biochem. J. 316 1996 57 63
43. M.B. Martin Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis Biochem. Biophys. Res. Commun. 263 1999 754 758
44. Y. Zhang Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation J. Am. Chem. Soc. 131 2009 5153 5162
45. J.H. No Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity Proc. Natl. Acad. Sci. U.S.A. 109 2012 4058 4063
46. Y. Zhang Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators Angew. Chem. Int. Ed. Engl. 49 2010 1136 1138
47. L. Wang Antibacterial effect of human Vγ2Vδ2 T cells in vivo J. Clin. Invest. 108 2001 1349 1357
48. C. Ellis Doing the two step Nat. Rev. Drug Discov. 2 2003 605
49. W.E. Courchesne Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone J. Pharm. Exp. Ther. 300 2002 195 199
50. S.S. Gupta Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis J. Biol. Chem. 278 2003 28831 28839
51. G. Benaim Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole J. Med. Chem. 49 2006 892 899
52. G. Benaim, and A.E. Paniz Mondolfi The emerging role of amiodarone and dronedarone in Chagas disease Nat. Rev. Cardiol. 9 2012 605 609
53. A.E. Paniz-Mondolfi Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug Ther. Clin. Risk Manag. 4 2008 659 663
54. A.E. Paniz-Mondolfi Amiodarone and itraconazole: a rational therapeutic approach for the treatment of chronic Chagas' disease Chemotherapy 55 2009 228 233
55. M. Protopopova Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines J. Antimicrob. Chemother. 56 2005 968 974
56. K. Tahlan SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 56 2012 1797 1809
57. D. Ellis Amphotericin B: spectrum and resistance J. Antimicrob. Chemother. 49 2002 7 10
58. S. Cencig Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with ambisome PLoS Negl. Trop. Dis. 5 2011 e1216
59. R.A. Woods Resistance to polyene antibiotics and correlated sterol changes in 2 isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria J. Infect. Dis. 129 1974 53 58
60. Y-M. Zhang, and C.O. Rock Membrane lipid homeostasis in bacteria Nat. Rev. Microbiol. 6 2008 222 233
61. D.N. Wilson Ribosome-targeting antibiotics and mechanisms of bacterial resistance Nat. Rev. Microbiol. 12 2014 35 48
62. H. Bercovier Mycobacteria possess a surprisingly small number of ribosomal-RNA genes in relation to the size of their genome Biochem. Biophys. Res. Commun. 136 1986 1136 1141
63. J.C. Munday Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs J. Antimicrob. Chemother. 69 2014 651 663
64. K.J. Edwards Crystal structure of a pentamidine-oligonucleotide complex: Implications for DNA-binding properties Biochemistry 31 1992 7104 7109
65. T.J. Opperman The mechanism of antibacterial action of novel bis-indole antibiotics Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy Boston, Presentation F1-1631 2010 http://www.microbiotix.com/posters/ICAAC-2010/F1-1631%20Opperman%20et%20al%20ICAAC2010.pdf
66. S.N.J. Moreno Pentamidine is an uncoupler of oxidative phosphorylation in rat liver mitochondria Arch. Biochem. Biophys. 326 1996 15 20
67. L.S. Tsutsumi Progress in the discovery of treatments for C. difficile infection: a clinical and medicinal chemistry review Curr. Top. Med. Chem. 14 2014 152 175
68. Ravic, M. et al. (2012) Disposition of MGB-BP-3, a new class of antibacterial agent, after oral administration in a hamster model of severe Clostridium difficile associated diarrhoea (CDAD). In 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy
69. Institute of Medicine (US) Forum on Microbial Threats Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies: Workshop Summary 2010 National Academies Press
70. R.C. Allen Targeting virulence: can we make evolution-proof drugs? Nat. Rev. Microbiol. 12 2014 300 308
71. G.Y. Liu Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity J. Exp. Med. 202 2005 209 215
72. C. Potera Pigments of pathogens might provide golden antimicrobial opportunities ASM News 71 2005 450 451
73. C-I. Liu A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence Science 319 2008 1391 1394
74. J.K. Dickson Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the α-phosphonosulfonic acid moiety J. Med. Chem. 39 1996 661 664
75. E. Layre Molecular profiling of Mycobacterium tuberculosis identifies tuberculosinyl nucleoside products of the virulence-associated enzyme Rv3378c Proc. Natl. Acad. Sci. U.S.A. 111 2014 2978 2983
76. H-C. Chan Structure and inhibition of tuberculosinol synthase and decaprenyl diphosphate synthase from Mycobacterium tuberculosis J. Am. Chem. Soc. 136 2014 2892 2896
77. O.A. Chow Statins enhance formation of phagocyte extracellular traps Cell Host Microbe 8 2010 445 454
78. F.Y. Lin Dual dehydrosqualene/squalene synthase inhibitors: leads for innate immune system-based therapeutics ChemMedChem 7 2012 561 564
79. 4] proteins involved in isoprenoid biosynthesis Angew. Chem. Int. Ed. 53 2014 4294 4310
80. C.Y. Chen Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates PLoS Pathog. 9 2013 e1003501
81. G. Workalemahu Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity J. Immunol. 193 2014 708 721
82. O. Wilde The Importance of Being Earnest: A Trivial Comedy for Serious People 1899 L. Smithers & Co., London